These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 7886560

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M.
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

  • 31. Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma.
    Rao KP, Kizer J, Jones TJ, Anunciado A, Pepkowitz SH, Lazarchick J.
    Arch Pathol Lab Med; 1988 Jan; 112(1):47-50. PubMed ID: 2447850
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C, Fischer AM, Schlegel N, Rothschild C, Torchet MF, Dautzenberg MD, Aujard Y.
    Nouv Rev Fr Hematol (1978); 1988 Jan; 30(4):225-7. PubMed ID: 3143100
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment.
    Hauser I, Schneider B, Lechner K.
    Thromb Haemost; 1995 Jan; 73(1):1-5. PubMed ID: 7740477
    [Abstract] [Full Text] [Related]

  • 39. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A.
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [Abstract] [Full Text] [Related]

  • 40. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM, Janosević S.
    Haematologia (Budap); 2008 Jul; 12(1-4):183-8. PubMed ID: 317061
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.